Oragenics (OGEN) Competitors $1.50 +0.07 (+4.51%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$1.54 +0.04 (+2.66%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock OGEN vs. EVOK, TTNP, CMND, VIVS, VAXX, PLRZ, LIPO, INM, CERO, and CANFShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Evoke Pharma (EVOK), Titan Pharmaceuticals (TTNP), Clearmind Medicine (CMND), VivoSim Labs (VIVS), Vaxxinity (VAXX), Polyrizon (PLRZ), Lipella Pharmaceuticals (LIPO), InMed Pharmaceuticals (INM), CERo Therapeutics (CERO), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. Its Competitors Evoke Pharma Titan Pharmaceuticals Clearmind Medicine VivoSim Labs Vaxxinity Polyrizon Lipella Pharmaceuticals InMed Pharmaceuticals CERo Therapeutics Can-Fite BioPharma Oragenics (NYSE:OGEN) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Do institutionals and insiders hold more shares of OGEN or EVOK? 18.7% of Oragenics shares are owned by institutional investors. 4.9% of Oragenics shares are owned by insiders. Comparatively, 2.3% of Evoke Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is OGEN or EVOK more profitable? Oragenics has a net margin of 0.00% compared to Evoke Pharma's net margin of -43.80%. Evoke Pharma's return on equity of -101.91% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% Evoke Pharma -43.80%-101.91%-33.75% Which has preferable earnings and valuation, OGEN or EVOK? Evoke Pharma has higher revenue and earnings than Oragenics. Evoke Pharma is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenicsN/AN/A-$20.66M-$33.63-0.04Evoke Pharma$10.25M0.39-$5.35M-$2.87-0.94 Which has more volatility and risk, OGEN or EVOK? Oragenics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Does the media favor OGEN or EVOK? In the previous week, Oragenics had 5 more articles in the media than Evoke Pharma. MarketBeat recorded 5 mentions for Oragenics and 0 mentions for Evoke Pharma. Oragenics' average media sentiment score of 0.10 beat Evoke Pharma's score of 0.00 indicating that Oragenics is being referred to more favorably in the media. Company Overall Sentiment Oragenics Neutral Evoke Pharma Neutral SummaryOragenics beats Evoke Pharma on 7 of the 12 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.24M$790.73M$5.54B$20.72BDividend YieldN/A4.84%5.24%3.72%P/E Ratio-0.211.3527.4328.09Price / SalesN/A226.97420.9838.30Price / CashN/A23.4436.8922.53Price / Book2.476.298.044.58Net Income-$20.66M-$27.73M$3.18B$986.06M7 Day Performance-62.84%1.82%2.88%2.79%1 Month Performance-57.37%9.90%3.69%5.46%1 Year Performance-95.06%10.79%36.15%15.06% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenics0.2211 of 5 stars$1.51+4.5%N/A-95.1%$1.24MN/A-0.215High Trading VolumeEVOKEvoke PharmaN/A$2.71+1.7%N/A-57.9%$4.03M$10.25M-0.944Positive NewsTTNPTitan Pharmaceuticals0.3358 of 5 stars$4.31+1.2%N/A-17.1%$3.92M$180K-0.9410Gap DownCMNDClearmind Medicine0.6124 of 5 stars$0.89+2.3%N/A-26.8%$3.81MN/A-0.81N/AVIVSVivoSim LabsN/A$1.47+1.0%N/AN/A$3.81M$140K-0.1420Positive NewsVAXXVaxxinityN/A$0.03+29,900.0%N/A-90.3%$3.80MN/A-0.0790PLRZPolyrizonN/A$0.71-1.7%N/AN/A$3.79MN/A0.00N/ANews CoveragePositive NewsGap DownLIPOLipella Pharmaceuticals1.356 of 5 stars$0.84flatN/A-77.9%$3.75M$536.36K-0.214INMInMed Pharmaceuticals1.0687 of 5 stars$3.02-2.3%N/A-42.8%$3.66M$4.60M-0.2510Analyst UpgradeGap UpCEROCERo Therapeutics3.301 of 5 stars$9.37+1.6%$45.00+380.1%-98.2%$3.66MN/A0.008Gap UpCANFCan-Fite BioPharma2.7243 of 5 stars$1.03-0.9%$14.00+1,257.9%-57.9%$3.65M$674K-0.588Gap Up Related Companies and Tools Related Companies Evoke Pharma Competitors Titan Pharmaceuticals Competitors Clearmind Medicine Competitors VivoSim Labs Competitors Vaxxinity Competitors Polyrizon Competitors Lipella Pharmaceuticals Competitors InMed Pharmaceuticals Competitors CERo Therapeutics Competitors Can-Fite BioPharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OGEN Stock Alerts